



## **ABIVAX to present at the BIO Europe 2015 conference and at the Deutsches Eigenkapitalforum**

October 15, 2015

Paris, October 15, 2015 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a publicly traded, clinical stage biotech company developing and commercializing therapeutic anti-viral drugs and vaccines, today announced the participation of its CEO, Prof. Dr. Hartmut Ehrlich, at the BIO Europe 2015 conference, to be held in Munich on November 2<sup>nd</sup> to 4<sup>th</sup>, and at the Deutsches Eigenkapitalforum to be held in Frankfurt on November 23<sup>rd</sup> and 24<sup>th</sup>. Prof. Ehrlich will make presentations on ABIVAX's current development program and strategy at both .